SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors and will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations. Her track record in capital raising and financial management is expected to be instrumental as SSII scales its operations and seeks regulatory clearance in the U.S. market.
The appointment comes at a critical juncture for SS Innovations, which is headquartered in India but incorporated in the U.S. The company’s flagship product, the SSi Mantra surgical robotic system, aims to make robotic surgery more affordable and accessible globally. With Romano’s expertise, the company is positioned to strengthen its balance sheet and navigate the complex financial landscape required to bring the system to the U.S. market. The SSi Mantra system is designed for a variety of procedures, including cardiac surgery, and is supported by the SSi Mudra suite of surgical instruments.
For business leaders, this move signals SS Innovations’ commitment to financial discipline and strategic growth. Romano’s experience in reducing cash burn and raising capital suggests the company is focused on achieving profitability while investing in innovation. The pursuit of FDA approval represents a significant milestone that could disrupt the surgical robotics market, currently dominated by established players. If approved, the SSi Mantra could offer a cost-effective alternative, potentially expanding access to robotic surgery in hospitals and clinics worldwide.
Investors should note that the company’s forward-looking statements involve risks and uncertainties, as outlined in its SEC filings. However, the appointment of a seasoned CFO like Romano, who has a proven ability to navigate public markets and regulatory environments, provides a layer of confidence. The full press release is available at this link.
SS Innovations’ vision to make robotic surgery affordable and accessible aligns with broader industry trends toward value-based care and technological democratization. As the company advances its global expansion, including potential FDA approval, the impact on the medical device industry could be substantial, offering new options for surgical precision and patient outcomes.
